Figure 2. Medium-throughput drug screening of peritonoids reveals shared and specific drug sensitivities to targeted agents.

Clinical and molecular features summarised (top), non-supervised clustering of normalised dose response AUC data from ex vivo medium-throughput drug testing of peritonoids depicted below (red 100% viable cells to blue 0% viable cells, normalised to vehicle alone). Matched samples: C, tumoroid derived from primary colorectal cancer; P, peritonoid derived from CRPM. CMS, consensus molecular subtype, WT, wild type; MUT, mutant; CNG, copy number gain; CNL, copy number loss; NA, not available